Pyxis Oncology (PYXS) EBT (2020 - 2025)
Pyxis Oncology's (PYXS) quarterly EBT came in at -$17.0 million in Q4 2025, up 54.94% year-on-year from -$11.0 million in Q4 2024, and up 22.72% on a QoQ basis from -$22.0 million in Q3 2025.
Pyxis Oncology (PYXS) EBT (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of EBT data on file, last reported at -$17.0 million in Q4 2025.
- On a quarterly basis, EBT rose 54.94% year-over-year to -$17.0 million in Q4 2025; TTM through Dec 2025 was -$79.6 million, a 9.48% increase from a year earlier, with the FY2025 full-year figure at -$78.2 million, up 1.59% from the prior year.
- EBT for Q4 2025 stood at -$17.0 million, up from -$22.0 million in the prior quarter.
- Over the last five years, EBT for PYXS reached as high as -$5.9 million in Q2 2021 and fell as low as -$46.4 million in Q3 2021.
- Historically, EBT has averaged -$26.0 million across 5 years, with a median of -$23.3 million in 2023.
- Across the five-year window, EBT plunged 1353.15% in 2021 and soared 54.94% in 2025, its largest moves.
- Year by year, EBT stood at -$32.8 million in 2021, then retreated by 8.01% to -$35.5 million in 2022, then jumped by 50.45% to -$17.6 million in 2023, then tumbled by 114.73% to -$37.7 million in 2024, then surged by 54.94% to -$17.0 million in 2025.
- Per Business Quant data, the three most recent EBT figures were -$17.0 million in Q4 2025, -$22.0 million in Q3 2025, and -$18.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -17.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Mar 31, 2025 | -22.56 Mn |
| Dec 31, 2024 | -37.74 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Dec 31, 2023 | -17.57 Mn |
| Sep 30, 2023 | -23.99 Mn |
| Jun 30, 2023 | -17.90 Mn |
| Mar 31, 2023 | -25.63 Mn |
| Dec 31, 2022 | -35.46 Mn |
| Sep 30, 2022 | -40.79 Mn |
| Jun 30, 2022 | -39.05 Mn |
| Mar 31, 2022 | -31.82 Mn |
| Dec 31, 2021 | -32.83 Mn |
| Sep 30, 2021 | -46.37 Mn |
| Jun 30, 2021 | -5.94 Mn |
| Mar 31, 2021 | -35.73 Mn |